By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.
Form 8.3 - SXS LN | 08-Oct-2025 | 15:30 | RNS |
Form 8.3 - Spectris plc | 08-Oct-2025 | 15:25 | RNS |
Form 8.3 - Spirent Communications plc | 08-Oct-2025 | 15:25 | Business Wire |
Form 8.3 - Spectris plc | 08-Oct-2025 | 15:25 | Business Wire |
Form 8.3 - NCC Group plc | 08-Oct-2025 | 15:20 | RNS |
Questor:Meggitt | 23-Dec-2014 | Telegraph |
Questor :Ricardo | 31-Oct-2014 | Telegraph |
Questor:CSR | 17-Oct-2014 | Telegraph |
Questor:BAE Systems | 03-Sep-2014 | Telegraph |
Questor :Sage Group | 09-May-2014 | Telegraph |
Price | 8,097.78 |
Closing Price Change | -7.06 |
% Change | 0.00 % |
07-Oct-25 Close | 8,097.78 |
You are here: research